Bioanalysis Zone

Bio-Techne and Refeyn have announced the launch of an integrated analytical workflow designed to address a persistent challenge in the development of bispecific antibodies and biosimilars. The new approach combines imaged capillary isoelectric focusing (icIEF) fractionation with mass photometry, making it possible to analyze both charge and size variations in complex biologic molecules within approximately 4 hours.

The technology aims to provide deeper insights into the therapeutic candidates while reducing the time and sample volumes required for testing.

Find out more here:

New workflow simplifies bispecific antibody and biosimilar characterization A new analytical workflow developed by Bio-Techne and Refeyn could simplify the characterization of bispecific antibodies and biosimilars.

What are the biggest bioanalytical challenges in transitioning from small molecules to therapeutic oligonucleotides?

In our latest Ask the Experts feature, Basile Khara, Kevork Mekhssian and Long Yuan discuss the strategies involved in transitioning from small molecules to oligonucleotides, as well as the valuable learnings from peptide and protein bioanalysis, and where these approaches diverge.

Find out more here >>>

https://hubs.ly/Q04gM3yY0
Waters Corporation

Ask the Experts: bioanalysis of therapeutic oligonucleotides In this Ask the Experts feature with Waters Corporation, our experts investigate the bioanalysis of therapeutic oligonucleotides, diving into a broad exploration of the unique challenges, strategies and innovations involved in this specialized area of bioanalysis.

𝗪𝗲𝗶𝗴𝗵𝗶𝗻𝗴 𝘂𝗽 𝘃𝗶𝗿𝗮𝗹 𝘃𝗲𝗰𝘁𝗼𝗿𝘀 𝘃𝘀 𝗟𝗡𝗣𝘀

QPS, LLC's Zamas Lam reviews the advantages and disadvantages of lipid nanoparticles and viral vectors for gene-based therapeutic delivery, including their immunogenicity risks, transduction efficiency and manufacturing considerations.

Read the full Editorial here >>>

Choosing the right delivery vehicle: navigating the trade-offs between LNPs and viral vectors In this expert option, Zamas Lam reviews the advantages and disadvantages of LNPs and viral vectors for gene-based therapeutic delivery.